Summary: The gout is the most common inflammatory arthropathy and is caused by the deposition of monosodium urate crystals during hyperuricemia. Hyperuricemia may also play a role in the metabolic syndrome and diseases accompanying metabolic syndrome. New diagnostic criteria were developed to improve gout diagnosis and management. The treatment has two phases – management of acute gout attack and its prevention by lowering uric acid levels. Colchicine plays and important role in the management of gout attack. It is also a first line drug in gout attacks prevention during uric acid lowering therapy. Colchicine also plays a role in the management of other diseases, including some cardiovascular diseases, and indications for its use may be extended in the future. Two products of colchicine are available on the market – their composition differs slightly, however, it is uncertain if it is of any clinical importance.